The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.

Colombo, N., Conte, P., Pignata, S., Raspagliesi, F., Scambia, G. (2016). Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 97, 335-348 [10.1016/j.critrevonc.2015.08.017].

Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives

COLOMBO, NICOLETTA
Primo
;
2016

Abstract

The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.
Articolo in rivista - Articolo scientifico
Anti-angiogenic; Bevacizumab; Front-line; Ovarian cancer; Phase III; Vascular endothelial growth factor;
Anti-angiogenic; Bevacizumab; Front-line; Ovarian cancer; Phase III; Vascular endothelial growth factor
English
10-ago-2015
2016
97
335
348
none
Colombo, N., Conte, P., Pignata, S., Raspagliesi, F., Scambia, G. (2016). Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 97, 335-348 [10.1016/j.critrevonc.2015.08.017].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/99991
Citazioni
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 18
Social impact